232 related articles for article (PubMed ID: 24603328)
21. Recommendations for modification of terminology of neuroblastic tumors and prognostic significance of Shimada classification. A clinicopathologic study of 213 cases from the Pediatric Oncology Group.
Joshi VV; Cantor AB; Altshuler G; Larkin EW; Neill JS; Shuster JJ; Holbrook CT; Hayes FA; Castleberry RP
Cancer; 1992 Apr; 69(8):2183-96. PubMed ID: 1544124
[TBL] [Abstract][Full Text] [Related]
22. Frequency of ALK and GD2 Expression in Neuroblastoma.
Aygün Z; Batur Ş; Emre Ş; Celkan T; Özman O; Comunoglu N
Fetal Pediatr Pathol; 2019 Aug; 38(4):326-334. PubMed ID: 30955398
[No Abstract] [Full Text] [Related]
23. ERBB3 is a marker of a ganglioneuroblastoma/ganglioneuroma-like expression profile in neuroblastic tumours.
Wilzén A; Krona C; Sveinbjörnsson B; Kristiansson E; Dalevi D; Øra I; De Preter K; Stallings RL; Maris J; Versteeg R; Nilsson S; Kogner P; Abel F
Mol Cancer; 2013 Jul; 12(1):70. PubMed ID: 23835063
[TBL] [Abstract][Full Text] [Related]
24. Podoplanin lymphatic density and invasion correlate with adverse clinicopathologic and biological factors and survival in neuroblastomas.
Ramani P; Somerville MS; May MT
Am J Surg Pathol; 2012 Jun; 36(6):908-15. PubMed ID: 22588067
[TBL] [Abstract][Full Text] [Related]
25. High levels of expression and nuclear localization of interleukin-1 beta converting enzyme (ICE) and CPP32 in favorable human neuroblastomas.
Nakagawara A; Nakamura Y; Ikeda H; Hiwasa T; Kuida K; Su MS; Zhao H; Cnaan A; Sakiyama S
Cancer Res; 1997 Oct; 57(20):4578-84. PubMed ID: 9377572
[TBL] [Abstract][Full Text] [Related]
26. Brain lipid-binding protein: a marker of differentiation in neuroblastic tumors.
Retrosi G; Sebire NJ; Bishay M; Kiely EM; Anderson J; De Coppi P; Resca E; Rampling D; Bier N; Mills K; Eaton S; Pierro A
J Pediatr Surg; 2011 Jun; 46(6):1197-200. PubMed ID: 21683222
[TBL] [Abstract][Full Text] [Related]
27. Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN.
Koppen A; Ait-Aissa R; Koster J; Øra I; Bras J; van Sluis PG; Caron H; Versteeg R; Valentijn LJ
Int J Cancer; 2008 Apr; 122(7):1455-64. PubMed ID: 18059033
[TBL] [Abstract][Full Text] [Related]
28. Role of diffusion-weighted imaging in distinguishing thoracoabdominal neuroblastic tumours of various histological types and differentiation grades.
Wen Y; Peng Y; Duan XM; Zhang N
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):718-724. PubMed ID: 28508462
[TBL] [Abstract][Full Text] [Related]
29. Genetic and Histopathological Heterogeneity of Neuroblastoma and Precision Therapeutic Approaches for Extremely Unfavorable Histology Subgroups.
Shimada H; Ikegaki N
Biomolecules; 2022 Jan; 12(1):. PubMed ID: 35053227
[TBL] [Abstract][Full Text] [Related]
30. The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors.
de Torres C; Beleta H; Díaz R; Toran N; Rodríguez E; Lavarino C; García I; Acosta S; Suñol M; Mora J
Cancer; 2009 Jun; 115(12):2792-803. PubMed ID: 19350667
[TBL] [Abstract][Full Text] [Related]
31. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status.
Giannini G; Kim CJ; Di Marcotullio L; Manfioletti G; Cardinali B; Cerignoli F; Ristori E; Zani M; Frati L; Screpanti I; Guilino A
Br J Cancer; 2000 Dec; 83(11):1503-9. PubMed ID: 11076660
[TBL] [Abstract][Full Text] [Related]
32. The clinical management and outcomes of cervical neuroblastic tumors.
Jackson JR; Tran HC; Stein JE; Shimada H; Patel AM; Marachelian A; Kim ES
J Surg Res; 2016 Jul; 204(1):109-13. PubMed ID: 27451875
[TBL] [Abstract][Full Text] [Related]
33. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee.
Shimada H; Ambros IM; Dehner LP; Hata J; Joshi VV; Roald B
Cancer; 1999 Jul; 86(2):349-63. PubMed ID: 10421272
[TBL] [Abstract][Full Text] [Related]
34. A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.
Xie Y; Xu H; Fang F; Li Z; Zhou H; Pan J; Guo W; Zhu X; Wang J; Wu Y
Am J Surg Pathol; 2018 Aug; 42(8):1027-1035. PubMed ID: 29794872
[TBL] [Abstract][Full Text] [Related]
35. Extra-adrenal peripheral neuroblastic tumors: A clinicopathological study of 18 cases.
Shankaralingappa S; Patra S; Gami A; Trivedi P; Chalaliya AK
Indian J Pathol Microbiol; 2023; 66(2):278-285. PubMed ID: 37077068
[TBL] [Abstract][Full Text] [Related]
36. CD44s expression correlated with the International Neuroblastoma Pathology Classification (Shimada system) for neuroblastic tumours.
Munchar MJ; Sharifah NA; Jamal R; Looi LM
Pathology; 2003 Apr; 35(2):125-9. PubMed ID: 12745459
[TBL] [Abstract][Full Text] [Related]
37. Enteric neural crest differentiation in ganglioneuromas implicates Hedgehog signaling in peripheral neuroblastic tumor pathogenesis.
Gershon TR; Shiraz A; Qin LX; Gerald WL; Kenney AM; Cheung NK
PLoS One; 2009 Oct; 4(10):e7491. PubMed ID: 19834598
[TBL] [Abstract][Full Text] [Related]
38. GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours.
Ramani P; Headford A; May MT
Virchows Arch; 2013 Feb; 462(2):203-9. PubMed ID: 23307190
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic Value of Diffusion-Weighted MRI for Tumor Characterization, Differentiation and Monitoring in Pediatric Patients with Neuroblastic Tumors.
Neubauer H; Li M; Müller VR; Pabst T; Beer M
Rofo; 2017 Jul; 189(7):640-650. PubMed ID: 28511265
[No Abstract] [Full Text] [Related]
40. High Oct4 expression: implications in the pathogenesis of neuroblastic tumours.
Monferrer E; Burgos-Panadero R; Blanquer-Maceiras M; Cañete A; Navarro S; Noguera R
BMC Cancer; 2019 Jan; 19(1):1. PubMed ID: 30606139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
